Tardive dyskinesia typically appears as repetitive, involuntary movements of the mouth, tongue, jaw, face or limbs. Patients may chew without food, protrude or twist the tongue, blink repeatedly, grimace, rock the feet or perform irregular movements of the fingers and trunk. The symptoms can fluctuate, becoming more obvious during stress or voluntary movement and less visible when a person is relaxed. Because psychotic and mood disorders can themselves affect motor behaviour, and because antipsychotic treatment may cause several other movement syndromes, diagnosis is not always straightforward. The review highlights the importance of distinguishing tardive dyskinesia from drug-induced parkinsonism, akathisia, acute dystonia and other abnormal movements that require different clinical responses.

At the centre of the disorder is the brain’s dopamine system. Most conventional antipsychotics, and many newer agents to a lesser degree, reduce signalling through dopamine D2 receptors. This action is therapeutically valuable because excessive dopamine activity in specific neural circuits is linked to psychotic symptoms. Over prolonged exposure, however, some neurons may adapt by becoming more responsive to dopamine. This process, often described as dopamine-receptor supersensitivity, is one of the leading explanations for tardive dyskinesia. When the medication dose changes or dopamine signalling fluctuates, the altered circuitry may produce involuntary movements. The biological picture is not limited to a single receptor: researchers also discuss changes involving gamma-aminobutyric acid, glutamate, serotonin, oxidative stress and inflammatory pathways.

The vulnerability appears to be unevenly distributed across patients. Age is one of the most consistently recognised clinical correlates, with older adults generally facing a higher risk than younger patients. The cumulative duration and intensity of exposure to dopamine-blocking drugs are also important, although tardive dyskinesia can develop after comparatively limited treatment in susceptible individuals. The paper considers how sex, metabolic illness, smoking, cognitive impairment and the severity or chronicity of the underlying psychiatric disorder may influence risk. A history of electroconvulsive treatment or previous movement abnormalities may also complicate assessment. These factors should not be interpreted as simple causes; rather, they form a network of clinical signals that can help physicians identify patients who need closer monitoring.

The comparison between schizophrenia spectrum disorders and mood disorders is especially important. Antipsychotics are used in both settings, but the treatment histories and patterns of exposure may differ. A person with schizophrenia may receive antipsychotic medication continuously for years, while a person with bipolar disorder or severe depression may encounter repeated courses during manic, psychotic or treatment-resistant episodes. Mood disorders can also carry their own motor and behavioural features, potentially masking early tardive symptoms. At the same time, people with mood disorders may develop the condition even when their overall exposure seems lower than expected, suggesting that individual susceptibility, age, coexisting medical conditions and medication combinations matter as much as a simple treatment-duration calculation.

The neurobiological discussion reaches beyond dopamine receptors to the circuitry that coordinates movement. Tardive dyskinesia is commonly linked to dysfunction in cortico-striato-thalamo-cortical loops, networks connecting the cerebral cortex with the basal ganglia and thalamus. These circuits select, initiate and suppress movement. If inhibitory control within the striatum becomes unstable, unwanted motor patterns may escape the brain’s filtering systems. Oxidative stress may add to the damage by generating reactive molecules that neurons cannot adequately neutralise. Mitochondrial dysfunction, altered GABAergic inhibition and glutamatergic excitability have each been proposed as contributors. The review presents tardive dyskinesia as the outcome of interacting adaptations rather than a single chemical defect, helping explain why symptoms vary widely between individuals.

Genetics may be another piece of the puzzle. Differences in genes involved in dopamine receptors, drug metabolism, synaptic plasticity, antioxidant defence and inflammatory signalling could affect how the nervous system responds to chronic medication exposure. Yet genetic findings have not produced a definitive clinical test. The same uncertainty applies to proposed blood, imaging and electrophysiological biomarkers. Brain-imaging studies have suggested changes in basal-ganglia function and connectivity, but these findings are not sufficiently consistent to diagnose an individual patient. The authors’ synthesis therefore supports a cautious interpretation: biological markers may eventually improve prediction and personalised treatment, but careful clinical observation remains the essential tool for now.

That observation must begin before symptoms become unmistakable. Standardised instruments such as the Abnormal Involuntary Movement Scale can help clinicians document facial, oral, limb and body movements at baseline and during follow-up. Regular assessment is particularly important when antipsychotic therapy is initiated, increased or continued over long periods. Patients and families should be told that repetitive movements deserve attention rather than being dismissed as nervous habits or signs of psychiatric deterioration. If tardive dyskinesia is suspected, clinicians must balance movement risk against the danger of destabilising the underlying illness. Abruptly stopping an antipsychotic can worsen psychosis or mania and may temporarily intensify dyskinetic movements, making an individualised plan essential.

The therapeutic landscape has expanded beyond simply reducing or changing antipsychotic medication. Vesicular monoamine transporter 2 inhibitors, including valbenazine and deutetrabenazine, can reduce abnormal movements by regulating the packaging and release of dopamine in nerve terminals. Switching to an antipsychotic with a lower movement-disorder risk may be considered in selected cases, while supportive treatment can address distress, social embarrassment and functional limitations. The new analysis reinforces the need to treat tardive dyskinesia as a long-term neurological and psychiatric issue rather than an unavoidable price of effective care. Its broader message is timely: understanding who develops the disorder, how brain circuits adapt and why symptoms persist could lead to earlier detection, safer prescribing and therapies designed around the biology of each patient.

Subject of Research: Clinical and neurobiological correlates of tardive dyskinesia in schizophrenia spectrum disorders and mood disorders

Article Title: Clinical and neurobiological correlates of tardive dyskinesia in schizophrenia spectrum disorders and mood disorders

Article References: Altinok, D.C.A., Volkmer, S., Fritze, S. et al. Clinical and neurobiological correlates of tardive dyskinesia in schizophrenia spectrum disorders and mood disorders. Schizophr 12, 69 (2026). https://doi.org/10.1038/s41537-026-00796-1

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41537-026-00796-1

Keywords: tardive dyskinesia, schizophrenia spectrum disorders, mood disorders, antipsychotic medication, dopamine, basal ganglia, neurobiology, movement disorders

Antipsychotics, particularly SGAs, have transformed schizophrenia management by offering improved efficacy and tolerability over first-generation agents. However, a significant downside is their propensity to induce metabolic alterations including weight gain, dyslipidemia, and glucose dysregulation. These metabolic disturbances significantly elevate the risk for cardiovascular diseases, contributing to the diminished life expectancy observed in this population. While aripiprazole and risperidone are among the most commonly deployed SGAs, their differential influence on metabolic parameters outside the framework of first-episode psychosis had remained insufficiently characterized until now.

Conducted over the course of seven weeks, this rigorous trial enrolled 60 patients with established schizophrenia diagnoses. Participants, either naïve to antipsychotic treatment or after a washout period, were randomized to receive either aripiprazole (dosed from 5 to 30 mg/day) or risperidone (2 to 10 mg/day). The study’s primary endpoint centered on changes in body mass index (BMI), a key metric linked to metabolic risk. Secondary outcomes included waist circumference, blood pressure, fasting lipid profiles, treatment-emergent adverse events (TEAEs), and detailed assessments of changes in appetite—an often overlooked but potentially critical factor in metabolic health.

Upon completion, with 57 patients adhering through the full seven-week period, the results were striking. Individuals treated with risperidone exhibited a notably greater increase in BMI compared to those receiving aripiprazole, with mean changes of +1.1 ± 0.3 versus +0.4 ± 0.2, respectively, a difference that was highly statistically significant (p < 0.001). This finding underscores the more pronounced weight gain linked to risperidone over a relatively short treatment window, a factor that could predict longer-term metabolic complications if left unchecked.

In addition to weight metrics, the lipid profile trends further differentiated the two drugs, although these differences did not achieve statistical significance in this study. Patients on risperidone experienced larger elevations in triglycerides (+28.1 mg/dL vs. +7.3 mg/dL) and total cholesterol (+5.1 mg/dL vs. +0.1 mg/dL) compared to their aripiprazole counterparts. These shifts, while subtle, align with a broader pattern associating risperidone with adverse lipid changes, which, in clinical contexts, contribute cumulatively to cardiovascular risk.

Arguably, one of the most novel aspects of this investigation was its nuanced exploration of appetite changes as a mediating mechanism linking antipsychotic treatment to metabolic outcomes. Remarkably, appetite suppression was significantly more prevalent with aripiprazole (60.7% of patients) than with risperidone (20.7%), whereas increased appetite was more commonly reported by patients treated with risperidone (55.2% vs. 39.3%). This dichotomy in appetite effects not only offers plausible biological explanations for the differential weight gain observed but also highlights appetite monitoring as a feasible early clinical marker for subsequent metabolic trajectory.

Beyond metabolic concerns, the trial verified that both antipsychotics were comparably effective in reducing psychiatric symptoms, as measured by the Positive and Negative Syndrome Scale (PANSS). Baseline demographics, illness duration, and initial symptom severity were similar across groups, bolstering confidence that metabolic differences were attributable primarily to pharmacological properties rather than confounding clinical variables.

The methodological robustness of this study is noteworthy. The double-blind design minimized bias, while generalized estimating equations (GEE) addressed missing data, ensuring analytical rigor. Compliance, a common challenge in psychopharmacological trials, was carefully monitored using pill counts and structured interviews, confirming adherence without compromising data integrity.

Clinically, these findings advocate for a more personalized approach in antipsychotic therapy, emphasizing metabolic risk profiles alongside psychiatric efficacy. The relatively favorable metabolic footprint of aripiprazole, particularly its association with appetite suppression and less weight gain, may guide clinicians in tailoring treatment plans, especially for patients predisposed to cardiometabolic disorders. Moreover, incorporating routine appetite assessments during antipsychotic initiation could serve as a simple yet powerful tool to anticipate and mitigate adverse metabolic outcomes.

This study also invites future research trajectories. Longer-term investigations are essential to fully characterize the cumulative metabolic effects of these medications over extended treatment periods. Elucidating the neurobiological underpinnings of appetite modulation by different antipsychotics could unlock novel therapeutic targets, potentially enabling the development of agents that minimize metabolic risk without sacrificing antipsychotic efficacy.

In sum, the research presents compelling evidence that differentiates aripiprazole from risperidone not only in metabolic consequences but also in the clinical potential to leverage appetite changes as predictive markers. Such insights mark a significant advance in schizophrenia care, with the promise to enhance patient quality of life through harmonized management of psychiatric and metabolic health.

As schizophrenia remains a chronic condition demanding lifelong intervention, integrating metabolic risk assessment and mitigation into standard clinical protocols is more imperative than ever. The nuanced profiles unveiled by this trial reinforce that the choice of antipsychotic medication extends beyond symptom control, encompassing a broader commitment to safeguarding long-term physical wellness.

Ultimately, studies like this set the stage for a paradigm shift towards truly individualized schizophrenia treatment, harmonizing psychiatric stabilization with metabolic preservation. The clinical community and patients alike stand to benefit from these evidence-based refinements, making strides toward more holistic and sustainable therapeutic outcomes.

Subject of Research: Metabolic impacts of aripiprazole versus risperidone in schizophrenia treatment

Article Title: Assessing the metabolic impact of aripiprazole versus risperidone in the treatment of schizophrenia: a randomized double-blind controlled clinical trial

Article References:
Rahimi Darehbagh, R., Ghanizadeh, A. & Seyedoshohadaei, S.A. Assessing the metabolic impact of aripiprazole versus risperidone in the treatment of schizophrenia: a randomized double-blind controlled clinical trial. BMC Psychiatry 25, 1097 (2025). https://doi.org/10.1186/s12888-025-07496-7

Image Credits: AI Generated

DOI: 18 November 2025